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Abstract
Purpose of Review The purpose of the review is to examine
recent evidence on the effects of intravenous thrombolysis and
identify the remaining uncertainties.
Recent Findings We review the results of two large trials (the
third International Stroke Trial (IST-3) and The Enhanced
Control of Hypertension and Thrombolysis Stroke Study
(ENCHANTED)) and the publications from the individual
patient data analyses of the trials of alteplase conducted by
the Stroke Thrombolysis Trialists Collaboration.
Summary Despite about a 2% risk of fatal intracerebral
haemorrhage, on average, adult patients of all ages treated
with 0.9 mg/kg alteplase within 4.5 h will have better
long-term functional outcome. The use of a lower dose
of alteplase (0.6 mg/kg) is associated with a lower risk
of haemorrhage but its effect on functional outcome has
not been proven to be non-inferior to standard dose ther-
apy. Some clinicians feel confident to treat selected pa-
tients who present beyond 4.5 h or have unknown time of
onset, but many also agree that the current trials and other
research is needed to reliably define the optimum imaging
methods and treatment eligibility criteria.
Keywords Ischaemic stroke . Thrombolytic therapy .
Alteplase . Intracerebral haemorrhage . Functional outcome .
Imaging
Introduction
The majority of acute ischaemic strokes are the result of the
occlusion of a cerebral artery, though the nature of the arterial
obstruction can be very variable. [1] Commonly, large cere-
bral vessels are occluded by emboli (consisting of thrombus or
other material) which reach the cerebral circulation from the
chambers of the heart or great vessels while smaller vessels
may be occluded by intrinsic vessel wall disease (such as
lipohyalinosis, arteritis or other pathologies). As a treatment
for acute ischaemic stroke, intravenous administration of fi-
brinolytic drugs is targeted chiefly on large vessel occlusion
and aims to promote lysis of any emboli that contain fibrin.
Clot lysis leads to reperfusion of ischaemic brain and should
improve the chance of stroke recovery, but this benefit may be
negated by an increased risk of intracerebral haemorrhage.We
review recent evidence on the factors that influence the bal-
ance of benefits and harms of this important treatment.
Recent Evidence from Large Randomised
Controlled Trials
The publication of the results of third International Stroke
Trial (IST-3), the largest ever trial of intravenous (iv) throm-
bolysis with alteplase (0.9 mg/kg), with 3035 patients, dou-
bled the world evidence base on iv alteplase. [2] The study had
two unique features; it included a wider range of patients than
previous studies, chiefly patients aged over 80 years
(n = 1617) and followed them for up to 3 years (previous
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studies followed-up for just 3 months). [3, 4•] These data were
then included in the individual patient data meta-analysis of
the nine major trials of alteplase conducted by the Stroke
Thrombolysis Trialists Collaboration (including 6756
patients) [5••]. This review concluded: ‘Irrespective of age
or stroke severity, and despite an increased risk of fatal intra-
cranial haemorrhage during the first few days after treatment,
alteplase significantly improves the overall odds of a good
stroke outcome when delivered within 4·5 h of stroke onset,
with earlier treatment associated with bigger proportional ben-
efits’. [5••]
The Need to Remove the Upper Age Limit
for Treatment
The STTC data [5••] prompted the UK drug regulatory agency
to suggest that there was a case for the 80-year upper age limit
for treatment specified in the EU approval for alteplase to be
reconsidered. [6]We strongly support this view, so the product
licence, the summary of product characteristics and treatment
guidelines should all be aligned to permit treatment of people
aged over 80 years.
What Factors Do and Do Not Influence Risk
of Intracerebral Bleeding?
Age and Time to Treatment See Table 1. The new data
clearly show that neither increasing time to treatment nor in-
creasing age have a significant influence on the relative risk of
intracerebral bleeding [5••, 7••]
Stroke Severity By contrast, baseline stroke severity has a
substantial effect; the absolute risk of fatal intracranial bleed-
ing is lowest in mild stroke and highest in more severe stroke
[7••] (Table 1).
Antiplatelet Therapy Patients who receive antiplatelet drugs
in the 48 h before their stroke onset have a higher risk of
intracerebral bleeding, but have the same likelihood of a good
functional recovery as those who do not. [8] By contrast, the
co-administration of aspirin with the thrombolytic causes a
sufficient increase in bleeding to negate any benefit on func-
tional outcome. [9] The Enhanced Control of Hypertension
and Thrombolysis Stroke Study (ENCHANTED) trial also
suggested that patients already receiving dual antiplatelet ther-
apy might receive greater net benefit with lower dose
(0.6 mg/kg) alteplase.
Absolute Benefit from iv Thrombolysis Depends
on Baseline Stroke Severity
Figure 1 shows the expected effect of thrombolysis in people
with different baseline levels of stroke severity, ranging from
mild (National Institutes of Health Stroke Scale (NIHSS ≤5) to
very severe (NIHSS >22)). When making the decision about
whether to treat or not, it is the absolute risks of fatal bleeding
and of a good outcome that matter the most. People with mild
stroke will make a good recovery, even without thrombolysis
(small absolute benefit), while in severe stroke, the proportion
of patients becoming independent in activities of daily living
is small and not greatly influenced by treatment (small abso-
lute benefit). However, on average, for many patients with a
Table 1 Risk of fatal
intracerebral haemorrhage and
modelled absolute excess due to
alteplase in different subgroups.
The absolute excess risk (and its
95% confidence interval (CI)) for
each subgroup is estimated by
applying the odds ratio among all
randomised patients to the
average expected risk among
control-allocated patients for that
subgroup (estimated from a
logistic regression model adjusted
for trial, treatment allocation, the
subgroup of interest and average
levels of the other two baseline
characteristics) [7••]
Alteplase (n = 3391) Control (n = 3365) Modelled absolute excess (95% CI)
Treatment delay
≤3.0 h 22/787 (2.8%) 2/762 (0.3%) 1.6% (0.6–2.6%)
>3 to ≤4.5 h 35/1375 (2.5%) 7/1437 (0.5%) 2.1% (1.1–3.0%)
>4.5 h 34/1229 (2.8%) 4/1166 (0.3%) 1.9% (1.0–2.8%)
Age
≤80 years 59/2512 (2.3%) 9/2515 (0.4%) 2.0% (1.2–2.8%)
>80 years 32/879 (3.6%) 4/850 (0.5%) 1.7% (0.7–2.7%)
Baseline NIHSS
0–4 3/345 (0.9%)1 0/321 (0.0%) NE
5–10 20/1281 (1.6%) 5/1252 (0.4%) 1.3% (0.6–1.9%)
11–15 23/794 (2.9%) 1/808 (0.1%) 1.9% (0.9–2.9%)
16–21 24/662 (3.6%) 5/671 (0.7%) 2.6% (1.3–4.0%)
≥22 21/309 (6.8%) 2/313 (0.6%) 4.1% (1.8–6.4%)
All patients 91/3391 (2.7%) 13/3365 (0.4%)
NE not estimable
1 Note: With an observed frequency of 3 fatal ICH among 345 patients allocated alteplase, the 95% CI for 0.9%
proportion with ICH is 0-1.8%
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non-trivial stroke, thrombolysis can be expected to ‘shift’
treated patients of at least moderate severity towards a lesser
degree of neurological impairment and disability than those
not treated. Even though iv thrombolysis is of net benefit, it is
not a cure-all. For example, of patients with a moderate to
severe stroke (NIHSS 11–15) treated with iv thrombolysis,
one would expect 39% to be alive and independent, but 61%
would be expected to die or be dependent on others in activ-
ities of daily living. Such patients, who despite thrombolytic
therapy are not expected to make a full recovery, may then be
candidates for endovascular therapy (e.g. mechanical clot re-
trieval with a stent retriever device). [10] In our view, the
priority is to ensure all patients with non-trivial strokes are
considered for iv thrombolysis and all eligible patients treated
as promptly as possible. There is debate as to whether or not it
is necessary to give iv thrombolysis before endovascular treat-
ment (we think it is), but ongoing trials such as SWIFT
DIRECTwill help to answer the question.
Controversies About Patient Selection
Mild Stroke Patients with baseline NIHSS can be expected to
do well without treatment; however, if the stroke causes a
deficit such as isolated hemianopia or isolated aphasia, the
NIHSS will be low, and the person’s quality of life may be
Fig. 1 Estimated proportion of patients in each mRS score category with
or without alteplase, according to stroke severity at baseline. An mRS of
0–1 indicates an excellent outcome: survival symptom free or with
residual symptoms with no loss of activity. mRS 5–6 indicates bed
bound or dead at 3–6 months. In IST-3, 125 (4.1%) of 3035 patients
died between 3 and 6 months. For comparability of mRS 6 between
IST-3 and the other trials (which assessed mRS scores at 3 months),
these patients were reassigned an mRS of 5 for this analysis. NIHSS
National Institutes of Health Stroke Scale, mRS modified Rankin Scale,
IST-3 Third International Stroke Trial. Reproduced with permission,
Elsevier from Stroke Thrombolysis Trialists Collaboration 2016 [7••].
NNT for mRS 0–1 is 10 within 3 h, 19 from 3 to 4.5 h and 50 from 4.5
to 6 h. Reproduced from Fig. 4 in. Whiteley et al., Risk of intracerebral
haemorrhage with alteplase after acute ischaemic stroke: a secondary
analysis of an individual patient data meta-analysis. Lancet Neurol
2016; 15: 925–33
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very adversely affected. Yet, treatment plausibly carries a 1%
risk of fatal intracranial bleeding, and hence the discussions
with the patient and the family to weigh up potential benefits
and harms may be very difficult because of the uncertainties.
As a result, two trials comparing thrombolysis with control in
patients with mild stroke are ongoing to resolve the uncertain-
ty, PRISMS and TEMPO-2 (Table 2).
Severe Stroke Some individuals with severe stroke may be
prepared to accept a high (4%, or 1 in 25) immediate risk of
fatal haemorrhage from treatment if their prognosis is poor
(the person has ‘nothing to lose’), whereas for others, that
level of risk may be unacceptably high. Better clinical deci-
sion aids are needed to support clinicians and patients in deal-
ing with the difficult discussions that can arise in these cir-
cumstances. [7••]
Choice of Imaging Modality for Routine Cases Facilities
and local practice in the use of imaging to select patients for
reperfusion therapy varies widely around the world. [11] For
routine cases of stroke, where the time of onset is known
reliably and treatment can be given within 4.5 h, we have a
strong personal preference for rapid non-contrast CT as the
imaging method of first choice to exclude haemorrhage, and
if the stroke is moderate to severe, and endovascular therapy is
rapidly available locally, CT angiography (CTA) is in addi-
tion. Demchuk et al. argue that CTA should become the min-
imum standard of care in acute disabling ischaemic stroke.
[12]
Imaging for Endovascular Therapy, Late-Presenting
(>4.5 h), Wake-up and Unknown Time of Onset Stroke
This is a controversial topic; criteria vary enormously and only
1% meet a common set of criteria. [13] In well-resourced
centres where multimodal MR scanning is available, some
experts feel confident to select cases for treatment on the basis
of advanced imaging findings. However, there is no consensus
on precisely what the imaging selection parameters for treat-
ment should be and there is no ‘clear winner’. Current trials
aim to better define the criteria for patient selection and given
the limited availability of multimodal MR in some sites, the
TWIST trial is evaluating the use of CT and CT angiography
in wake-up stroke (Table 2). The DEFUSE 3 trial of
endovascular therapy versus control also permits the use of
either CTorMR perfusion and angiography for case selection.
[14] When CTA and MRA are not available, transcranial
Doppler ultrasound, in experienced hands gives a good indi-
cation of vessel patency [15].
Patients on Oral Anticoagulants Depending on age, one
sixth to one third of all acute ischaemic stroke patients are in
atrial fibrillation, and many are on long-term oral anticoagu-
lants when they arrive at the hospital, which creates problems
for clinicians considering thrombolytic or endovascular
therapy.[16, 17] Rapid reversal of Vitamin-K based
anticoagulation to achieve an INR of <1.7 to permit iv throm-
bolysis is difficult [16]. The situation for patients treated with
the novel direct oral anticoagulants (DOACs) is changing rap-
idly with the introduction into clinical practice of agents that
can rapidly reverse the direct thrombin inhibitor dabigatran
(idarucizumab). A small case series suggests that reversal of
dabigatran prior to iv thrombolysis is safe [18], and Diener
and others have proposed a management algorithm to handle
such cases. [17] The agent that reversed factor X (adexanet)
will be available in the near future.
Dose of Alteplase Is a lower dose of iv alteplase preferable?
The ENCHANTED study compared standard dose
(0.9 mg/kg) with lower dose (0.6 mg/kg) alteplase [19].
Major symptomatic intracerebral haemorrhage occurred in
1.0% of the participants in the low-dose group and in 2.1%
of the participants in the standard-dose group (P = 0.01).
However, in terms of the effect on the proportion dead or
disabled at 90 days, the lower dose did not meet the criteria
for noninferiority. [19] The lower dose is widely used in Asia,
and as a result of the trial, many clinicians will continue to use
the lower dose because of fears of haemorrhage, despite the
potential loss of efficacy. By contrast, in the West, clinicians
may well tend to continue with the guideline approved stan-
dard dose, unless there is a particular concern about bleeding
risk. [20]
Planning Service Delivery There has been much debate
about how best to organise stroke services to deliver re-
perfusion therapy to ensure the largest number of patients
benefit. Most strokes occur in low and middle income
countries, where delivery of basic acute stroke care is
challenging [21] and beyond the scope of this article. As
a result, the use of iv thrombolysis varies enormously
around the world. In a systematic review of worldwide
use of thrombolysis for stroke Berkowitz found that, of
214 countries and independent territories, 64 (30%) re-
ported use of intravenous the average percentage treated
tissue plasminogen activator for acute ischemic stroke; in
the medical literature is 3% (1/36) of low-income, 19%
(10/54) lower-middle-income, 33% (18/54) of upper-
middle-income and 50% (35/70) of high-income-
countries (test for trend, P < 0·001). [22] Within high-
income countries like the USA, the proportion treated
varies geographically [23], and treatment is not delivered
to all that might benefit, though treatment rates are im-
proving [24]. To deliver IVT/EVT equitably and afford-
ably across a region or a country must be adapted to local
resources will be a challenge, even for advanced econo-
mies, [23] and is beyond the scope of this article.
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Conclusions
These new data confirm clearly that ‘time is brain’ and that the
priority remains rapid recognition of stroke, transport to hospital
with a fast-track stroke thrombolysis system of clinical and radio-
logical assessment followed by prompt treatment with iv throm-
bolysis where appropriate or inclusion in a relevant trial designed
to resolve one of the current uncertainties. These goals are best
achieved within a well organised and dedicated stroke unit.
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